Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1576, Issue 1-2, 2002, Pages 101-109

  Olie, Robert A ^a   Hall, Jonathan ^b   Natt, Francois ^b   Stahel, Rolf A ^a   Zangemeister Wittke, Uwe ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

2 modification; Backbone modification; bcl 2 bcl xL antisense; Oligonucleotide chemistry

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGONUCLEOTIDE; PROTEIN BCL 2; PROTEIN BCL XL; RIBONUCLEOTIDE;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL LINE; CELL VIABILITY; LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUMOR CELL; WESTERN BLOTTING;

APOPTOSIS; BCL-X PROTEIN; CARCINOMA, SMALL CELL; CELL DIVISION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; LUNG NEOPLASMS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0037036151     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(02)00300-7     Document Type: Article

References (39)

1. Does antisense exist?
2. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines
3. The therapeutic potential of antisense oligonucleotides
4. Anti-sense oligodeoxynucleotides - Promises and pitfalls
5. Gene inhibition using antisense oligodeoxynucleotides
6. Pharmacology of antisense oligonucleotide inhibitors of protein expression
7. Antisense oligonucleotides
8. Conformational preorganization, hydration, and nucleic acid duplex stability
9. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
10. The ups and downs of nucleic acid duplex stability: Structure-stability studies on chemically-modified DNA:RNA duplexes
11. Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity
12. Anti-tumor activity of C-raf antisense
13. Potent activity of a novel bcl-2/bcl-xL bispecific antisense oligonucleotide against tumors of diverse histological origin
14. Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment
15. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
16. Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines
17. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides
18. Bcl-xL antisense treatment induces apoptosis in breast carcinoma cells
19. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines
20. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells
21. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in malignant melanoma cells of different clinical stages
22. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
23. Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis)
24. Kinetic characteristics of Escherichia coli RNase H1: Cleavage of various antisense oligonucleotide-RNA duplexes
25. Molecular mechanisms of antisense drugs: RNase H
26. Antisense inhibitory effect: A comparison between 3′-partial and full phosphorothioate antisense oligonucleotides
27. Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotide on human complement and coagulation
28. A new access to 2′-O-alkylated ribonucleosides and properties of 2′-O-alkylated oligoribonucleotides
29. Antisense therapeutics: Is it as simple as complementary base recognition?
30. Antisense therapeutics
31. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression
32. Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and enonuclease sensitivity and ability to form RNase H substrates
33. Bcl-2 family proteins as targets for anticancer drug design
34. Bcl-2 and Bcl-xL can differentially block chemotherapy-induced cell death
35. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: Progress and therapeutic potential
36. Backbone modifications in oligonucleotides and peptide nucleic acid systems
37. The direction of ribonucleases H by antisense oligodeoxynucleotides
38. Study of antisense oligonucleotide phosphorothioates containing segments of 2′O-methyloligoribonucleotides
39. Hybrid oligonucleotides: Synthesis, biophysical properties, stability studies and biological activity